I never would have guessed a most difficult and time-consuming proof-of-concept study for epinephrine, let alone a long-winded set of clinical trials should that work out, would do so much for INSY.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.